Live in-person:

30 Jan - 2 Feb 2023

Dubai World Trade Centre

Online

4 Jan - 2 Mar 2023

A new scalable mobile platform for accelerating the future of human-centered digital healthcare

 

Cellspect

 

Wednesday 26th January | 15:00

Transformation Zone | S2.D70

 

Product description


Cellspect Point-of-Care Testing


Cellspect’s innovative Point-of-Care Testing (POCT) solutions are ushering you to a new era of simple, fast, and accurate blood testing which can be easily done by yourself at home, work, or anywhere else. Cellspect has also improved conventional POCT into smart device-driven POCT that enables detection by using mobile Apps, bringing true self-testing to a new digital age.

 

Company bio


Abdul Latif Jameel Health introduces: Cellspect
 

Abdul Latif Jameel General Trading based in Tokyo, Japan, part of the diversified family business Abdul Latif Jameel, announced a new collaboration with Cellspect for the distribution of the Cellspect blood testing in the Middle East, Africa, Southeast Asia, and India.
Cellspect, based in Japan, develops and produces next-generation POCT (Point of Care Testing) devices that detects multiple parameters simultaneously from limited samples, such as fingertip blood. Moreover, in the view of the rapidly changing digital transformation, Cellspect has improved POCT into smart device-driven POCT which enables detection by using mobile Apps. Currently, biochemical tests such as ‘sugar metabolism’, ‘lipid’ and COVID-19 antigen/antibody are available and more tests on cardiovascular diseases, infectious diseases, and even customized tests will be released in the future. By providing items and tools that allow people to easily know their health, Cellspect would like to take on the challenge of realizing “Barrier-Free Health” that allows anyone to access healthcare freely.

Presenters


Dr. Akram Bouchenaki
CEO Abdul Latif Jameel Health

Akram Bouchenaki is Chief Executive Officer of Abdul Latif Jameel Health, Abdul Latif Jameel’s health care business, focusing on accelerating access to modern medical care while addressing unmet medical needs in developing markets around the World. Abdul Latif Jameel Health is part of Abdul Latif Jameel, a collective of independent international, family-owned and diversified businesses, founded in 1945 by the late Abdul Latif Jameel.

Dr. Bouchenaki joins Abdul Latif Jameel Health after 25 years of operational and strategic roles in the pharmaceutical and healthcare sectors, including global leadership roles in ‘big-pharma’ corporates as well as in top California-based biotech, where he was an executive director for Africa covering the largest markets on the continent.

Akram has extensive knowledge and experience of both generics and branded medicines in established as well as key emerging markets across the world. These include Africa’s most significant markets, Brazil, and Mexico, having co-founded a fast-growing start-up to commercialize medicines in Latin America.

Akram holds a Doctorate in Pharmacy from Université de Paris V, France. He has lived and worked in 9 different countries across 5 continents. He speaks French, Spanish, Arabic, Portuguese and English.

Mr. Takuya IWABUCHI
CEO, Cellspect

After working as a special research faculty member at the Center for Integrated Medical Research (CIMR), Keio University School of Medicine, and as a major diagnostic drug manufacturer, he established Metallogenics Co., Ltd. in 2010 to develop new in-vitro diagnostic agents for the management of psychiatric drug treatment, and succeeded in licensing out to major pharmaceutical and medical device companies. In 2017, he received the JAPAN VENTURE AWARD nominated by the President of the Small and Medium Enterprises Organization, and the Tohoku Entrepreneur Grand Prize. In 2020, Cellspect Co., Ltd, which he founded in 2014, won the top award from the SMBC Startup Support Program in recognition of its emergency response for pandemic countermeasures. In addition, he received the Resona Bank Award from the Star At Pitch Japan of The Nikkei (formally The Nihon Keizai Shimbun - Japan Economics Newspaper) for the business of extending healthy life expectancy.

Mr. Nguyen Huu DIEP
Director, Cellspect

He started his career for 9 years as a researcher at the Vietnam Academy of Science & Technology in the field of mechatronics. He holds two master's degrees including a Degree of Master in Mechatronics from Vietnam National University, Vietnam, and a Master of Science of System Engineering in System Design and Management from Keio University, Japan. His expertise is in systems engineering related to precision dynamics and mechatronics for mechatronic systems. Currently, he is focusing on promoting international collaborations in launching new business models of POCT all over the world.

Mr. Hiroshi Takai
Director, Cellspect